The Calypte^® HIV-1 BED Incidence EIA is an in vitro quantitative enzyme immunoassay for the determination of the proportion of HIV-1 specific IgG in a given serum or plasma specimen with respect to total IgG as an aid in determining the elapsed time since HIV-1 infection occurred. The Calypte HIV-1 BED Incidence EIA is to be used for public health purposes only, such as for population incidence estimates to assist in prevention programs, targeting resources, monitoring and evaluation, and identifying high risk cohorts for prevention research, including vaccine trials. The assay is not for diagnosis of HIV infection.